UNSPSC 51162610: Bibenzonium bromide

This classification denotes an antitussive agent with the molecular formula C19H26NO.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4455J9277Q, chemically known as (2-(1,2-diphenylethoxy)ethyltrimethyl)ammonium bromide but more generally known as bibenzonium bromide, which bears US NIH Compound Identifier 85001. European Medicines Agency schedules Bibenzonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05815MIG.

UNSPSC 51162610 Bibenzonium bromide is a Commodity code that in recent state and local procurement activity captures pharmaceutical products and drug-related supplies, though the code designation itself does not align clearly with the actual scope of work being solicited. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are sourcing naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and RFP processes. The work spans pharmaceutical manufacturing and supply-chain coordination, with vendors required to hold cGMP certification, comply with FDA requirements and the Drug Supply Chain Security Act, maintain contractual relationships with authorized wholesalers, and manage electronic data interchange (EDI) systems. Issuing bodies include county health departments and state cooperative purchasing alliances that represent multiple member jurisdictions. Vendors must carry comprehensive insurance including commercial general liability coverage of $5 million per occurrence and professional liability of $2 million, and are subject to performance penalties for late reporting or missed onboarding timelines.

Seminole County, Florida and Minnesota (through MMCAP, which also serves Oregon) represent the recent geographic activity identified in the source. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting a date inconsistency in the source); the contract includes a two-year term with one-year renewal option and potential FEMA funding. MMCAP issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with proposals due March 26, 2026 and awarded contracts effective July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on compliance, EDI capability, and administrative fee agreement. The code shows limited recent activity and poor alignment between its nominal scope (bibenzonium bromide, a specific chemical compound) and the actual pharmaceutical and drug-supply procurement being transacted.